ACOG Quote, Financials, Valuation and Earnings

Actinium Pharmaceuticals, Inc. has a net margin of -46.4% compared to Alpha Cognition, Inc.'s net margin of -5701.11%. Alpha Cognition, Inc.'s return on equity of -67.07% beat Actinium Pharmaceuticals, Inc.'s return on equity of -133.63%.

Alpha Cognition, Inc. has a consensus price target of $31.18, signalling upside risk potential of 259.71%. On the other hand Actinium Pharmaceuticals, Inc. has an analysts' consensus of $5.00 which suggests that it could grow by 195.86%. Given that Alpha Cognition, Inc. has higher upside potential than Actinium Pharmaceuticals, Inc., analysts believe Alpha Cognition, Inc. is more attractive than Actinium Pharmaceuticals, Inc..

Alpha Cognition, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Actinium Pharmaceuticals, Inc. has a beta of -0.367, suggesting its less volatile than the S&P 500 by 136.662%.

Alpha Cognition, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Actinium Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Alpha Cognition, Inc. pays -- of its earnings as a dividend. Actinium Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Alpha Cognition, Inc. quarterly revenues are $2.8M, which are larger than Actinium Pharmaceuticals, Inc. quarterly revenues of $90K. Alpha Cognition, Inc.'s net income of -$1.3M is higher than Actinium Pharmaceuticals, Inc.'s net income of -$5.1M. Notably, Alpha Cognition, Inc.'s price-to-earnings ratio is -- while Actinium Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alpha Cognition, Inc. is 11.11x versus 585.79x for Actinium Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

CEL-SCI Corp. has a net margin of -46.4% compared to Alpha Cognition, Inc.'s net margin of --. Alpha Cognition, Inc.'s return on equity of -67.07% beat CEL-SCI Corp.'s return on equity of -266.61%.

Alpha Cognition, Inc. has a consensus price target of $31.18, signalling upside risk potential of 259.71%. On the other hand CEL-SCI Corp. has an analysts' consensus of $42.50 which suggests that it could grow by 765.58%. Given that CEL-SCI Corp. has higher upside potential than Alpha Cognition, Inc., analysts believe CEL-SCI Corp. is more attractive than Alpha Cognition, Inc..

Alpha Cognition, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison CEL-SCI Corp. has a beta of 0.487, suggesting its less volatile than the S&P 500 by 51.259%.

Alpha Cognition, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CEL-SCI Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Alpha Cognition, Inc. pays -- of its earnings as a dividend. CEL-SCI Corp. pays out -- of its earnings as a dividend.

Alpha Cognition, Inc. quarterly revenues are $2.8M, which are larger than CEL-SCI Corp. quarterly revenues of --. Alpha Cognition, Inc.'s net income of -$1.3M is higher than CEL-SCI Corp.'s net income of -$5.7M. Notably, Alpha Cognition, Inc.'s price-to-earnings ratio is -- while CEL-SCI Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alpha Cognition, Inc. is 11.11x versus -- for CEL-SCI Corp.. Usually stocks with elevated PS ratios are considered overvalued.

IGC Pharma, Inc. has a net margin of -46.4% compared to Alpha Cognition, Inc.'s net margin of -953.4%. Alpha Cognition, Inc.'s return on equity of -67.07% beat IGC Pharma, Inc.'s return on equity of -94.42%.

Alpha Cognition, Inc. has a consensus price target of $31.18, signalling upside risk potential of 259.71%. On the other hand IGC Pharma, Inc. has an analysts' consensus of $3.88 which suggests that it could grow by 1191.67%. Given that IGC Pharma, Inc. has higher upside potential than Alpha Cognition, Inc., analysts believe IGC Pharma, Inc. is more attractive than Alpha Cognition, Inc..

Alpha Cognition, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison IGC Pharma, Inc. has a beta of 0.242, suggesting its less volatile than the S&P 500 by 75.839%.

Alpha Cognition, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. IGC Pharma, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Alpha Cognition, Inc. pays -- of its earnings as a dividend. IGC Pharma, Inc. pays out -- of its earnings as a dividend.

Alpha Cognition, Inc. quarterly revenues are $2.8M, which are larger than IGC Pharma, Inc. quarterly revenues of $191K. Alpha Cognition, Inc.'s net income of -$1.3M is higher than IGC Pharma, Inc.'s net income of -$1.8M. Notably, Alpha Cognition, Inc.'s price-to-earnings ratio is -- while IGC Pharma, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alpha Cognition, Inc. is 11.11x versus 22.51x for IGC Pharma, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals, Inc. has a net margin of -46.4% compared to Alpha Cognition, Inc.'s net margin of -255.85%. Alpha Cognition, Inc.'s return on equity of -67.07% beat NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03%.

Alpha Cognition, Inc. has a consensus price target of $31.18, signalling upside risk potential of 259.71%. On the other hand NovaBay Pharmaceuticals, Inc. has an analysts' consensus of $0.85 which suggests that it could fall by -83.96%. Given that Alpha Cognition, Inc. has higher upside potential than NovaBay Pharmaceuticals, Inc., analysts believe Alpha Cognition, Inc. is more attractive than NovaBay Pharmaceuticals, Inc..

Alpha Cognition, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals, Inc. has a beta of 0.569, suggesting its less volatile than the S&P 500 by 43.103%.

Alpha Cognition, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.80 per share. Alpha Cognition, Inc. pays -- of its earnings as a dividend. NovaBay Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Alpha Cognition, Inc. quarterly revenues are $2.8M, which are larger than NovaBay Pharmaceuticals, Inc. quarterly revenues of $521K. Alpha Cognition, Inc.'s net income of -$1.3M is higher than NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M. Notably, Alpha Cognition, Inc.'s price-to-earnings ratio is -- while NovaBay Pharmaceuticals, Inc.'s PE ratio is 8.90x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alpha Cognition, Inc. is 11.11x versus 10.30x for NovaBay Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.